Current evidence-based treatment of infantile hemangiomas

doi:10.19438/j.cjoms.2022.01.002

Abstract

Abstract: Infantile hemangioma is the most common benign tumor in childhood. Early intervention is currently advocated so as to minimize complications and negative effects on mental development. With the successful application of various β-blockers, the treatment methods have undergone revolutionary changes, and the treatment effect has also been improved. Based on literature review and evidence-based medicine, this article summarized the indications, advantages and disadvantages and selection of various treatment methods for infantile hemangioma, in order to provide guidance for clinical application.

Key words: Infantile hemangioma, Evidence-based treatment, Beta receptor blockers

CLC Number:

R739.8

ZHENG Jia-wei, ZHAO Ze-liang, CHEN Qi-ming. Current evidence-based treatment of infantile hemangiomas[J]. China Journal of Oral and Maxillofacial Surgery, 2022, 20(1): 7-14.

References

[1] Kilcline C, Frieden IJ.Infantile hemangiomas: how common are they? a systematic review of the medical literature[J]. Pediatr Dermatol,2008,25(2):168-173.
[2] 郑家伟. 婴幼儿血管瘤“等待观察”的治疗策略应予改变[J].中国口腔颌面外科杂志,2012,10(2):163-164.
[3] Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy[J]. N Engl J Med, 2008,358(24):2649-2651.
[4] Moyakine AV, Herwegen B, van der Vleuten CJM. Use of the Hemangioma Severity Scale to facilitate treatment decisions for infantile hemangiomas[J]. J Am Acad Dermatol, 2017,77(5):868-873.
[5] Janmohamed SR, de Waard-van der Spek FB, Madern GC, et al.Scoring the proliferative activity of haemangioma of infancy: the Haemangioma Activity Score (HAS)[J]. Clin Exp Dermatol, 2011,36(7):715-723.
[6] Haggstrom AN, Beaumont JL, Lai JS, et al.Measuring the severity of infantile hemangiomas: instrument development and reliability[J]. Arch Dermatol, 2012,148(2):197-202.
[7] Sebaratnam D, Rodríguez Bandera AI, Wong LF, et al.Infantile hemangioma. part 2: management[J]. Am Acad Dermatol, 2021,85(6):1395-1404.
[8] Overman J, Fontaine F, Wylie-Sears J, et al.R-propranolol is a small molecule inhibitor of the SOX18 transcription factor in a rare vascular syndrome and hemangioma[J]. ELife, 2019,8:e43026.
[9] Solman L, Glover M, Beattie PE, et al.Oral propranolol in the treatment of proliferating infantile haemangiomas: British Society for Paediatric Dermatology 406 consensus guidelines[J]. Brit J Dermatol, 2018,179(3):582-589.
[10] Smithson SL, Rademaker M, Adams S, et al.Consensus statement for the treatment of infantile haemangiomas with propranolol[J]. Australas J Dermatol, 2017,58(2):155-159.
[11] Shah SD, Baselga E, McCuaig C, et al. Rebound growth of infantile hemangiomas after propranolol therapy[J]. Pediatrics, 2016,137(4):e20151754.
[12] Caussé S, Aubert H, Saint-Jean M, et al.Propranolol-resistant infantile haemangiomas[J]. Brit J Dermatol,2013,169(1):125-129.
[13] Zhao ZL, Liu C, Zheng JW, et al.Oral atenolol treatment for infantile hemangiomas: clinical analysis of 133 consecutive patients[J]. Ann Transl Med,2021,9(2):116.
[14] 王琦,向波,吉毅,等.普萘洛尔与阿替洛尔治疗婴儿血管瘤的比较研究[J].中华皮肤科杂志,2016,49(10):683-687.
[15] Laurens C, Abot A, Delarue A, et al.Central effects of beta-blockers may be due to oxide and hydrogen peroxide release independently of their ability to cross the blood-brain barrier[J]. Front Neurosci, 2019,13:33.
[16] Aly MM, Hamza AF, Abdel Kader HM, et al.Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma[J]. Eur J Pediatr, 2015,174(11):1503-1509.
[17] Liu C, Zhao Z, Wu H, et al.Effect of combined low-dose oral prednisone with beta-adrenergic receptor antagonists for refractory infantile hemangiomas: retrospective cohort study in 76 patients[J]. Ann Transl Med, 2019,7(23):750.
[18] Gnarra M, Solman L, Harper J, et al.Propranolol and prednisolone combination for the treatment of segmental haemangioma in PHACES syndrome[J]. Br J Dermatol, 2015,173(1):242-246.
[19] Davila-Osorio VL, Iznardo H, Roe E, et al.Propranolol-resistant infantile hemangioma successfully treated with sirolimus[J]. Pediatr Dermatol, 2020,37(4):684-686.
[20] Zaher H, Rasheed H, El-Komy MM, et al.Propranolol versus captopril in the treatment of infantile hemangioma (IH): a randomized controlled trial[J]. J Amer Acad Dermatol, 2016,74(3):499-505.
[21] Wu HW, Liu C, Wang X, et al.Topical application of 0.5% timolol maleate hydrogel for the treatment of superficial infantile hemangioma[J]. Front Oncol,2017,7:137.
[22] M Hill I, Stefanko N, Drolet BA. Comment on "doing the math: a simple approach to topical timolol dosing for infantile hemangiomas"[J]. Pediatr Dermatol, 35(5):698-699.
[23] Danarti R, Ariwibowo L, Radiono S, et al.Topical timolol maleate 0.5% for infantile hemangioma: its effectiveness compared to ultrapotent topical corticosteroids - a single-center experience of 278 cases[J]. Dermatology, 2016,232(5):566-571.
[24] Hartmann F, Lockmann A, Gronemeyer LL, et al.Nd:YAG and pulsed dye laser therapy in infantile haemangiomas: a retrospective analysis of 271 treated haemangiomas in 149 children[J]. J Eur Acad Dermatol Venereol, 2017,31(8):1372-1379.
[25] Jin WW, Tong Y, Wu JM, et al.Observation on the effects of 595- nm pulsed dye laser and 755- nm long-pulsed alexandrite laser on sequential therapy of infantile hemangioma[J]. J Cosmet Laser Ther, 2020,22(3):159-164.
[26] Pandey V, Tiwari P, Sharma SP, et al.Role of intralesional bleomycin and intralesional triamcinolone therapy in residual haemangioma following propranolol[J]. Int J Oral Maxillofac Surg, 2018,47(7):908-912.
[27] Waner M.The surgical management of infantile hemangiomas[J]. Otolaryngol Clin North Am, 2018,51(1):125-131.
[28] Fernández Faith E, Shah S, Witman PM, et al.Clinical features, prognostic factors, and treatment interventions for ulceration in patients with infantile hemangioma[J]. JAMA Dermatol, 2021,157(5):566-572.
[29] Frieden IJ, Püttgen KB, Drolet BA, et al.Management of infantile hemangiomas during the COVID pandemic[J]. Pediatric Dermatol, 2020,37(3):412-418.